State-of-the-Art PaperInflammation in Atrial Fibrillation
Key Words
Abbreviations and Acronyms
Cited by (0)
Drs. Apostolakis and Lip have received research funding and honoraria from various pharmaceutical companies in relation to atrial fibrillation for meetings and educational symposia. Dr. Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola, and Boehringer Ingelheim; has been on the speaker's bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi Aventis; is a member of advisory boards and trial steering committees; he was clinical advisor to the UK National NICE Guidelines on Atrial Fibrillation Management; and was on the writing group for the European Society of Cardiology Guidelines on Atrial Fibrillation Management; he is also a panelist on the revised (9th edition) American College of Chest Physicians Guidelines on Antithrombotic Therapy. Dr. Guo has reported that he has no relationships relevant to the contents of this paper to disclose.